Please click on a company name to see details about that investment.
PAICE is a company that has been at the forefront of the hybrid-vehicle industry for nearly 20 years, developing technology capable of significantly improving driving performance, maximizing fuel efficiency, reducing harmful emissions, and lowering costs. Its inventions have been recognized with 13 U.S. patents and numerous foreign patents, including four of the world’s 10 most dominant hybrid vehicle patents according to a study by Griffith Hack. PAICE has established long-term licensing agreements with Toyota and Ford, two of the world’s largest automakers for its hybrid technology. For more information, visit www.PAICEhybrid.com.
ThermoChem Recovery International, Inc. (TRI)
TRI has developed a set of proprietary gasification technologies that provide the foundation for state-of-the-art conversion of biomass into green fuels, chemicals and renewable energy. TRI‘s steam-reforming gasification process converts cellulosic feedstocks (including post-sorted Municipal Solid Waste (MSW), bark, forest residuals, agricultural waste, energy crops and low rank coals) into a synthesis gas (“syngas”) which can be converted into biofuels and biochemical, or used to replace fossil fuels for power generation. TRI’s proprietary process uniquely removes contaminants in solid form, making it a particularly good technology for conversion of MSW, with far superior emissions as compared to existing waste-to-energy plants. TRI licenses its proprietary gasification technology—including biomass feeders, gasification and gas clean-up—and provides specialized equipment and engineering services to companies seeking to integrate TRI's process into their operations. TRI’s proven technology has been demonstrated at commercial scale at the Norampac Trenton mill in Ontario, Canada. For more information, visit www.tri-inc.net.
OTEC International LLC (OTI)
Ocean Thermal Energy Conversion (OTEC) is an important renewable energy technology that harnesses the vast solar energy stored in the upper layers of the tropical oceans to produce electricity. In contrast to conventional solar and wind projects, OTEC can generate power 24 hours a day, 365 days a year. OTI has developed proprietary designs, including 18 issued or U.S. patents pending, to efficiently convert this thermal energy into a commercially viable alternative to conventional fossil fuel power plants. Leveraging more than 40 years of OTEC R&D, OTI has received the first-ever approval in principal for its floating base load power plants and is in the forefront of commercial development with contracts in Hawaii and Grand Cayman. See www.oteci.com for additional information.
Ceratech, Inc. has pioneered and commercialized a product line of high performing green cement, which is comprised of more than 90 percent recycled waste streams. Founded in 2001 and based in Baltimore, MD, CeraTech’s concrete repair and rehabilitation products are currently in use by the U.S. military in combat operations around the world as well as domestic transportation departments, municipalities, aviation and port authorities, and commercial construction companies. CeraTech uses fly ash, a waste product of coal-fired power plants, to produce its high- performance cement. In 2011, CeraTech received strategic equity investments from three publicly traded companies to accelerate market penetration of its proprietary products, starting in the U.S. For more information, visit www.ceratechinc.com.
Lawrenceville Plasma Physics, Inc.
Lawrenceville Plasma Physics, Inc. is a pioneering high-technology corporation specializing in applications of plasma physics, including fusion power and high-power X-ray sources for infrastructure inspection. Its lead project is the development of a dense plasma focus (DPF) fusion generator, using hydrogen-boron (pB11) fuel, an approach called “Focus Fusion.” This work is aimed at producing an extremely economical, compact, environmentally safe and essentially inexhaustible source of electric energy that could be more than 10 times cheaper than any existing sources. The project has already achieved major experimental milestones, including the achievement of plasma confinement at energies equivalent to 2 billion degrees, high enough to fuse hydrogen and boron. More details are available at www.lawrencevilleplasmaphysics.com.
BioMarker Strategies is developing a novel automated tumor biopsy processing and testing system, called SnapPath™, designed to quickly test and analyze a patient’s live solid tumor sample at the point of biopsy. These functional, pathway-based, ex vivo biomarker tests will help guide an oncologist’s use of targeted cancer therapeutics. The SnapPath™ technology is also designed to reduce patient waiting times for molecular diagnostic test results from several weeks to several hours. The company is one of the first commercial tenants at the Johns Hopkins Science + Technology Park in East Baltimore developed by the Forest City-New East Baltimore Partnership. For more information, visit www.biomarkerstrategies.com.
Pixelligent Technologies produces proprietary groundbreaking nanocrystal additives that can be deployed in a wide variety of commercial applications including electronics, metal coatings, lubricants and the solar market. The company is the first in the field to demonstrate the ability to scale up the nanocrystal additive materials for commercial deployment. In its initial applications to the electronic and semiconductor markets, the nanocrystal additives dramatically improve the etch resistance—a critical step used to manufacture computer chips and enhance the efficiency and performance of digital displays and high brightness LEDs. Pixelligent is headquartered in Baltimore, MD. Visit www.pixelligent.com for additional information.
eNeura Therapeutics, a privately held medical technology company, has developed a portable, non-invasive Transcranial Magnetic Stimulation (TMS) device for treatment of migraine headaches. Many patients are unable to utilize traditional methods of treatment because of medications currently offered. With the use of magnetic pulsing, TMS allows migraine patients to administer treatment as needed. This technology has been approved and licensed for sale in Europe with expected FDA approval in the U.S. in 2014. For more information, visit www.eneura.com.
Network for Good
Network for Good is a fundraising technology platform that supports charitable giving through customized web pages and mobile applications. Network for Good combines storytelling and social marketing to engage and inspire tech savvy adults to areas of passion and commitment. The company uses a social media model for multiple non-profit organizations to efficiently fundraise small donations. Educational institutions and large nonprofits can private label their fundraising efforts and manage multiple donor channels leveraging the innovative platform. For more information, visit networkforgood.org.
Common Curriculum is an educational tool developed by two Teach For America graduates to innovate lesson planning, sharing and scheduling. This application provides an efficient tool for teachers and school districts to meet Common Core standards. Visit www.commoncurriculum.com for more information.
Noxilizer is a biotechnology company that has developed a faster, less expensive, environmentally friendly, room temperature NO2-based sterilizer for the medical industry. It is also developing a system especially for sensitive, high-tech equipment used in minimally invasive surgical procedures. For more information, visit www.noxilizer.com.
Gliknik is a bio-pharmaceuticals company that has developed new therapies for patients with cancer and autoimmune/inflammatory diseases. It also has commercial rights to two cancer immunomodulator drugs that are in multiple-dose clinical trials in patients with advanced head and neck cancer and in patients with advanced multiple myeloma. www.gliknik.com.
GrayBug is a biotech company with a proprietary drug for age-related macular degeneration (AMD) and other diseases that involve unwanted growth of new blood vessels. The company has two proprietary platform drug delivery technologies for ophthalmic pharmaceutical indications, and proof-of-concept (POC) data in multiple animal models for its lead product in AMD, diabetic retinopathy (DR), corneal graft rejection, and four different drugs for glaucoma. GrayBug has obtained an exclusive worldwide license to certain patents from the Johns Hopkins University School of Medicine. For more information, visit www.graybug.com
Sonify Biosciences exists to explore the potential of low-intensity ultrasound as a novel melanoma treatment.
Propel Baltimore Fund
The Propel Baltimore Fund (PBF) was created by The Abell Foundation, in conjunction with the Maryland Technology Development Corporation (TEDCO). The PBF, which is open to other institutional investors, was created to support the establishment and development of promising businesses in Baltimore and to help ensure that innovators recognize Baltimore as an attractive location to start, build, and sustain their companies. The Fund will provide up to a $250,000 investment in early-stage technology companies. See tedco.md/program/propel-baltimore-fund/ for more information.
Harpoon Medical, Inc.
Harpoon Medical, Inc. is a development stage medical device company commercializing a minimally invasive, image guided surgical tool for beating heart mitral valve repair. The technology was developed in the division of Cardiac Surgery at The University of Maryland School of Medicine. With the Harpoon device, surgeons can access and repair the mitral valve in a beating heart via a small incision between the ribs without the need for cardiac arrest or cardiopulmonary bypass. When introduced to the market, the Harpoon device should transform the traditional open heart mitral valve surgical procedure from a complex 3-6 hour operation to a 60-minute procedure and reduce the recovery period from weeks to days. See www.Harpoonmedical.com
Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX®, an immunotherapy for Stage II colon cancer that involves using the patient’s own cancer cells to prevent the disease from recurring. The vaccine has demonstrated its effectiveness and safety in early trials. The company has established the manufacturing capability to produce OncoVAX® for a Phase IIIb trial. See www.Vaccinogeninc.com
Divergent, Inc. is an early stage technology company that is developing a wireless solid state power supply unit for use in homes and offices. The company has developed an operating proof of concept prototype for its PowerMax Wireless Power converter using electro-scalar waves to produce energy.
Breethe, Inc. is committed to delivering new product options for patients suffering respiratory failure, cardiac arrest, and cardiopulmonary collapse. The initial focus is to bring the world’s first wearable out-of-hospital artificial lung to market. Based on unique technology developed at University of Maryland, Baltimore and supported by a $5 million NIH award, the company intends to move the use of the artificial lung into humans within the next 2-3 years. Breethe received an allocation of Maryland Biotechnology Tax Credits to support its fundraising efforts in 2014.
In the United States, nearly 29 million people, or 9% of the population, have diabetes, with an additional 8 million estimated to be undiagnosed. Globally, more than 371 million people currently suffer from diabetes, a population that is expected to grow to well over 550 million by 2030. Approximately 1 in 3 diabetics currently suffer from DR, a medical condition that can results in loss of vision from prolonged mismanagement of diabetes. Unfortunately, as few as 50% of diabetics receive the recommended annual eye exam, while up to 36% of diabetics have never had an exam.
Vasoptic Medical has developed a low-cost, easy-to-use, mobile detection device that rapidly captures information at an early stage and can be used in primary care offices and community clinic worldwide, allowing optical health information to be integrated into diabetes management systems. See www.vasopticmedical.com.
It is difficult to fully understand an investment opportunity based on a phone call. If you have a funding proposal for a company located or willing to locate in Baltimore City, please send us an executive summary and an email address where you can be reached.
Please send executive summaries either via email to firstname.lastname@example.org, or by mail to:
Robert C. Embry, Jr.
The Abell Foundation
111 S. Calvert Street
Baltimore, MD 21202-6174
Phone: (410) 547-1300
Fax: (410) 539-6579